Early Analysis of Tick Bite Data's Alpha-gal Treatment Experience Survey

One of the greatest challenges facing the Alpha-gal Syndrome community is the lack of standardized treatment recommendations. Patients are often left navigating a growing list of therapies—from dietary modifications and antihistamines to SAAT, mast cell stabilizers, biologics, supplements, and other interventions—with little data available to help predict who may benefit.

To better understand these experiences, Tick Bite Data recently launched a Treatment Experience Survey. While the survey is still in its early stages, the first 60 patient responses are already highlighting an important observation: Alpha-gal Syndrome does not appear to behave like a uniform disease.

An Early Look at Patient-Reported Outcomes

This analysis reflects the first 60 patient-reported treatment surveys submitted to Tick Bite Data. The findings should be viewed as exploratory and hypothesis-generating rather than definitive. Patient-reported experiences cannot establish treatment effectiveness or causation, but they can identify patterns that deserve further scientific investigation.

Among respondents evaluating their overall treatment experience, outcomes varied considerably:

• Some patients described treatment as life-changing.

• Others reported moderate or slight improvement.

• Many experienced no meaningful improvement.

• A small number reported their symptoms actually worsened following treatment.

  
  

Rather than clustering around a single outcome, responses were distributed across the entire spectrum of experiences.

If Alpha-gal Syndrome behaved as a single, predictable condition, we might expect patients receiving similar therapies to report similar results. Instead, these early findings suggest something far more complex.

Why Might Patients Respond So Differently?

Several factors could contribute to these differences.

Patients may vary in:

• The severity of their Alpha-gal Syndrome.

• Ongoing tick bite exposure.

• Degree of sensitivity to mammalian-derived ingredients.

• Presence of mast cell activation or other allergic conditions.

• Coexisting tick-borne illnesses.

• Underlying immune system differences.

• Length of time since diagnosis.

• Individual dietary and lifestyle factors.

Each of these variables may influence how someone responds to treatment. It is also possible that additional biological factors have yet to be identified.

At this stage, we simply do not know.

SAAT: A Good Example of Patient Diversity

One treatment frequently discussed within the Alpha-gal community is Soliman Auricular Allergy Treatment (SAAT). Among respondents who reported undergoing SAAT, experiences were similarly diverse. Some described dramatic improvement, while others reported little benefit or no change at all.

These findings should not be interpreted as evidence that SAAT is either effective or ineffective. Instead, they illustrate an important point: Patients living with Alpha-gal Syndrome are not all experiencing the same disease in the same way.

A Pattern We've Been Seeing Across Multiple Surveys

This observation is not limited to treatment experiences.

Over the past several years, Tick Bite Data has collected thousands of patient-reported surveys covering symptoms, food reactions, neurological involvement, medication reactions, tick exposures, geographic distribution, quality of life, and healthcare experiences.

Across these datasets, one consistent theme continues to emerge: People diagnosed with Alpha-gal Syndrome often report remarkably different clinical experiences.

Some experience primarily gastrointestinal symptoms.

Others experience recurrent anaphylaxis.

Many report neurological symptoms such as brain fog, dizziness, tremors, headaches, or cognitive dysfunction.

Others struggle with musculoskeletal pain, cardiovascular symptoms, chronic fatigue, medication reactions, or sensitivity to products that extend well beyond red meat.

No two patient stories look exactly alike.

What This Could Mean for Future Research

If future research confirms that Alpha-gal Syndrome consists of multiple biological subgroups—or varying disease phenotypes—it could help explain why:

• Treatments work well for some patients but not others.

• Symptoms vary dramatically between individuals.

• Some patients improve over time while others remain chronically ill.

• Certain patients react to dairy, gelatin, medications, or airborne exposures while others do not.

Understanding these differences may ultimately prove just as important as developing new treatments themselves.

Where We Go From Here

Sixty treatment surveys represent only the beginning.

As more patients contribute their experiences, these early observations will become stronger, allowing researchers to evaluate whether today's patterns remain consistent across hundreds—or eventually thousands—of responses.

Every completed survey adds another piece to the puzzle.

Every patient story helps move the scientific conversation forward.

At Tick Bite Data, our goal is not to promote any specific treatment or therapy.

Our goal is to identify meaningful patient-reported patterns that can guide future research, improve clinical understanding, and ultimately help answer one of the biggest questions facing the Alpha-gal community today: Is Alpha-gal Syndrome truly one disease—or are we witnessing multiple biological pathways that happen to share the same diagnosis?

The answer may shape the future of Alpha-gal research for years to come.